Cargando…

In Vitro Activity of Isavuconazole against Opportunistic Fungal Pathogens from Two Mycology Reference Laboratories

Monitoring antifungal susceptibility patterns for new and established antifungal agents seems prudent given the increasing prevalence of uncommon species associated with higher antifungal resistance. We evaluated the activity of isavuconazole against 4,856 invasive yeasts and molds collected worldwi...

Descripción completa

Detalles Bibliográficos
Autores principales: Pfaller, Michael A., Rhomberg, Paul R., Wiederhold, Nathan P., Gibas, Connie, Sanders, Carmita, Fan, Hongxin, Mele, James, Kovanda, Laura L., Castanheira, Mariana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Microbiology 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6153788/
https://www.ncbi.nlm.nih.gov/pubmed/30061288
http://dx.doi.org/10.1128/AAC.01230-18
_version_ 1783357573698682880
author Pfaller, Michael A.
Rhomberg, Paul R.
Wiederhold, Nathan P.
Gibas, Connie
Sanders, Carmita
Fan, Hongxin
Mele, James
Kovanda, Laura L.
Castanheira, Mariana
author_facet Pfaller, Michael A.
Rhomberg, Paul R.
Wiederhold, Nathan P.
Gibas, Connie
Sanders, Carmita
Fan, Hongxin
Mele, James
Kovanda, Laura L.
Castanheira, Mariana
author_sort Pfaller, Michael A.
collection PubMed
description Monitoring antifungal susceptibility patterns for new and established antifungal agents seems prudent given the increasing prevalence of uncommon species associated with higher antifungal resistance. We evaluated the activity of isavuconazole against 4,856 invasive yeasts and molds collected worldwide. The 4,856 clinical fungal isolates, including 2,351 Candida species isolates, 97 non-Candida yeasts, 1,972 Aspergillus species isolates, and 361 non-Aspergillus molds, including 292 Mucorales isolates collected in 2015 to 2016, were tested using CLSI methods. The MIC values for isavuconazole versus Aspergillus ranged from 0.06 to ≥16 μg/ml. The modal MIC for isavuconazole was 0.5 μg/ml (range, 0.25 [A. nidulans and A. terreus species complex] to 4 μg/ml [A. calidoustus and A. tubingensis]). Eight A. fumigatus isolates had elevated isavuconazole MIC values at ≥8 μg/ml (non-wild type). Isavuconazole showed comparable activity to itraconazole against the Mucorales. The lowest modal isavuconazole MIC values were seen for Rhizopus spp., R. arrhizus var. arrhizus, and R. microsporus (all 1 μg/ml). Candida species isolates were inhibited by ≤0.25 μg/ml of isavuconazole (range, 96.1% [C. lusitaniae] to 100.0% [C. albicans, C. dubliniensis, C. kefyr, and C. orthopsilosis]). MIC values were ≤1 μg/ml for 95.5% of C. glabrata isolates and 100.0% of C. krusei isolates. Isavuconazole was active against the non-Candida yeasts, including Cryptococcus neoformans (100.0% at ≤0.5 μg/ml). Isavuconazole exhibited excellent activity against most species of Candida and Aspergillus. Isavuconazole was comparable to posaconazole and voriconazole against the less common yeasts and molds. Isavuconazole was generally less active than posaconazole and more active than voriconazole against the 292 Mucorales isolates. We confirm the potentially useful activity of isavuconazole against species of Rhizopus as determined by CLSI methods.
format Online
Article
Text
id pubmed-6153788
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher American Society for Microbiology
record_format MEDLINE/PubMed
spelling pubmed-61537882018-09-28 In Vitro Activity of Isavuconazole against Opportunistic Fungal Pathogens from Two Mycology Reference Laboratories Pfaller, Michael A. Rhomberg, Paul R. Wiederhold, Nathan P. Gibas, Connie Sanders, Carmita Fan, Hongxin Mele, James Kovanda, Laura L. Castanheira, Mariana Antimicrob Agents Chemother Epidemiology and Surveillance Monitoring antifungal susceptibility patterns for new and established antifungal agents seems prudent given the increasing prevalence of uncommon species associated with higher antifungal resistance. We evaluated the activity of isavuconazole against 4,856 invasive yeasts and molds collected worldwide. The 4,856 clinical fungal isolates, including 2,351 Candida species isolates, 97 non-Candida yeasts, 1,972 Aspergillus species isolates, and 361 non-Aspergillus molds, including 292 Mucorales isolates collected in 2015 to 2016, were tested using CLSI methods. The MIC values for isavuconazole versus Aspergillus ranged from 0.06 to ≥16 μg/ml. The modal MIC for isavuconazole was 0.5 μg/ml (range, 0.25 [A. nidulans and A. terreus species complex] to 4 μg/ml [A. calidoustus and A. tubingensis]). Eight A. fumigatus isolates had elevated isavuconazole MIC values at ≥8 μg/ml (non-wild type). Isavuconazole showed comparable activity to itraconazole against the Mucorales. The lowest modal isavuconazole MIC values were seen for Rhizopus spp., R. arrhizus var. arrhizus, and R. microsporus (all 1 μg/ml). Candida species isolates were inhibited by ≤0.25 μg/ml of isavuconazole (range, 96.1% [C. lusitaniae] to 100.0% [C. albicans, C. dubliniensis, C. kefyr, and C. orthopsilosis]). MIC values were ≤1 μg/ml for 95.5% of C. glabrata isolates and 100.0% of C. krusei isolates. Isavuconazole was active against the non-Candida yeasts, including Cryptococcus neoformans (100.0% at ≤0.5 μg/ml). Isavuconazole exhibited excellent activity against most species of Candida and Aspergillus. Isavuconazole was comparable to posaconazole and voriconazole against the less common yeasts and molds. Isavuconazole was generally less active than posaconazole and more active than voriconazole against the 292 Mucorales isolates. We confirm the potentially useful activity of isavuconazole against species of Rhizopus as determined by CLSI methods. American Society for Microbiology 2018-09-24 /pmc/articles/PMC6153788/ /pubmed/30061288 http://dx.doi.org/10.1128/AAC.01230-18 Text en Copyright © 2018 Pfaller et al. https://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Epidemiology and Surveillance
Pfaller, Michael A.
Rhomberg, Paul R.
Wiederhold, Nathan P.
Gibas, Connie
Sanders, Carmita
Fan, Hongxin
Mele, James
Kovanda, Laura L.
Castanheira, Mariana
In Vitro Activity of Isavuconazole against Opportunistic Fungal Pathogens from Two Mycology Reference Laboratories
title In Vitro Activity of Isavuconazole against Opportunistic Fungal Pathogens from Two Mycology Reference Laboratories
title_full In Vitro Activity of Isavuconazole against Opportunistic Fungal Pathogens from Two Mycology Reference Laboratories
title_fullStr In Vitro Activity of Isavuconazole against Opportunistic Fungal Pathogens from Two Mycology Reference Laboratories
title_full_unstemmed In Vitro Activity of Isavuconazole against Opportunistic Fungal Pathogens from Two Mycology Reference Laboratories
title_short In Vitro Activity of Isavuconazole against Opportunistic Fungal Pathogens from Two Mycology Reference Laboratories
title_sort in vitro activity of isavuconazole against opportunistic fungal pathogens from two mycology reference laboratories
topic Epidemiology and Surveillance
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6153788/
https://www.ncbi.nlm.nih.gov/pubmed/30061288
http://dx.doi.org/10.1128/AAC.01230-18
work_keys_str_mv AT pfallermichaela invitroactivityofisavuconazoleagainstopportunisticfungalpathogensfromtwomycologyreferencelaboratories
AT rhombergpaulr invitroactivityofisavuconazoleagainstopportunisticfungalpathogensfromtwomycologyreferencelaboratories
AT wiederholdnathanp invitroactivityofisavuconazoleagainstopportunisticfungalpathogensfromtwomycologyreferencelaboratories
AT gibasconnie invitroactivityofisavuconazoleagainstopportunisticfungalpathogensfromtwomycologyreferencelaboratories
AT sanderscarmita invitroactivityofisavuconazoleagainstopportunisticfungalpathogensfromtwomycologyreferencelaboratories
AT fanhongxin invitroactivityofisavuconazoleagainstopportunisticfungalpathogensfromtwomycologyreferencelaboratories
AT melejames invitroactivityofisavuconazoleagainstopportunisticfungalpathogensfromtwomycologyreferencelaboratories
AT kovandalaural invitroactivityofisavuconazoleagainstopportunisticfungalpathogensfromtwomycologyreferencelaboratories
AT castanheiramariana invitroactivityofisavuconazoleagainstopportunisticfungalpathogensfromtwomycologyreferencelaboratories